Company intelligence / Profile preview
Zydus Lifesciences Limited
Ahmedabad, Gujarat, Indiazyduslife.com ↗
- Ownership
- Public · ZYDUSLIFE
- Employees
- ~25000
- Development stage
- Commercial
01
Overview
Zydus Lifesciences has multiple approved products including Saroglitazar for Nonalcoholic Steatohepatitis, Desidustat for chronic renal failure anemia, and biosimilars for Peginterferon alpha-2b, Adalimumab, and Interferon alpha-2b. The company also developed ZyCoV-D, the world's first DNA plasmid vaccine for COVID-19, which received emergency use authorization in 2021[8].
- Therapeutic areas
- OncologyEndocrinologyRheumatologyGastroenterologyCardiovascularNephrologyInfectious Diseases
- Modalities
- Small moleculesBiosimilarsMonoclonal antibodiesVaccinesDNA plasmid vaccines
- Industry
- Biotech
02
Drug pipeline
36 assets35 more assets in the full pipeline.
03
Partnerships
Central Drug Research Institute (CDRI)Gilead Sciences
Beyond the preview
Go deeper on Zydus Lifesciences Limited.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Zydus Lifesciences Limited.